Roche Reintroduces Wet AMD Eye Implant Nearly Two Years After Voluntary Recall

Published: Jul 09, 2024 By Tristan Manalac

Roche_iStock, JHVEPhoto

Pictured: Roche Diagnostics headquarters in California/iStock, JHVEPhoto 

Roche on Monday announced that it will reintroduce Susvimo (ranibizumab injection) in the U.S., which will make the eye implant available again for the treatment of patients with neovascular age-related macular degeneration.

Susvimo’s re-entry into the U.S. market comes after its voluntary market recall, announced in October 2022. According to Roche, the FDA has signed off on a post-approval supplement to Susvimo’s Biological License Application, which reflects updates to the components of the ocular implant and its refill needle.

Roche expects to make Susvimo available in the U.S. “in the coming weeks.”

CMO Levi Garraway in a statement said that Roche is “pleased to reintroduce Susvimo” into the U.S. market, again making available a “unique therapeutic approach shown to provide an…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks